In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Zev A. Wainberg, MD, discussed the significance of the AMPLIFY-201 trial, next steps for this vaccine platform, and the signs ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Dementia-like protein clumps found in pancreatic precancer mouse cells point to autophagy defects, offering cancer ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...